Avadel pharmaceuticals provides corporate update and reports third quarter 2023 financial results

-- $7.0 million in third quarter lumryz™ net revenue from u.s. commercial launch -- -- generated robust demand for lumryz with greater than 1,000 patients enrolled in ryzup tm and more than 400 patients initiating therapy as of september 30 --
AVDL Ratings Summary
AVDL Quant Ranking